

Original Research Article

Prevalence of *H. pylori* from Stool Samples of Patients Attending a Government Hospital in Port-Harcourt using Antigenic Screening and Culture-Based Techniques

Comment [SA1]: Change to detection as this is not a prevalence

ABSTRACT

Background: *Helicobacter pylori* is well-known among other bacteria causing ulcers, stomach cancer and other forms of gastrointestinal infections in developing countries.

Aim: This research was intended to evaluate the prevalence of *H. pylori* infection among patients attending a Government Hospital in Port-Harcourt, Rivers State Nigeria.

Methodology: One hundred and five (105) stool samples of individuals comprising of 48 males and 57 females were studied. The samples were investigated by antigenic screening using *H. pylori* stool antigen (HpSA) test kit. In addition, culture-based isolation was done using Columbia agar plus 10% horse blood, supplemented with antibiotics (amphotericin B, vancomycin, trimethoprim and ceftazidime).

Results: Out of 105 samples screened, 56 (53.3%) tested positive for both antigenic screening and culture-based techniques while 49 (46.7%) tested negative for both. Positive isolates were phenotypically characterized by colony morphology, Gram stain, and biochemical reactions and a total of 19 isolates were suspected to be *H. pylori*. The result indicated that *H. pylori* prevalence was relatively low in male (21.9%) compared to female (31.4%) using antigenic screening. However, the culture-based technique yielded low recovery in male (2.9%) compared to female (4.7%), making the prevalence of infection high among the female than the male. Age group prevalence increased with age, recording infections within age group ≥ 31 (20.0%) followed by 26-30, (12.3%) and lowest in age group 21-25 (10.5%) and below using antigenic screening. while in culture-based technique, age group 26-30, (3.8%) followed by ≥ 31 (3.8%) yielding low recovery, while age group 21-25 and below had 0 recovery. There was no significant difference ($P > 0.05$) among the different genders/age groups studied.

Conclusion: This study revealed a high level of *H. pylori* infection among the female than the male population sampled. To reduce the prevalence, regular screening, treatment and public health awareness campaign should be developed for the control, elimination and prevention of *H. pylori* infection.

Comment [SA2]: Distribution or infection rate

1. Introduction

Helicobacter pylori previously known as *Campylobacter pylori*, is a Gram-negative, microaerophilic, spiral (helical) bacterium usually found in the stomach [1]. Its helical body (from which the genus name, *Helicobacter* derives) is thought to have evolved in order to penetrate the mucous lining of the stomach, helped by its flagella, and thereby establish infection [2; 3]. *H. pylori* infection usually has no symptoms however typically causes gastritis (stomach inflammation) or ulcers of the stomach or first part of the small intestine. The infection is also associated with development of certain cancers occurring in less than 20% of cases [4].

In 2015, it was estimated that over 50% of the world's population had *H. pylori* in their upper gastrointestinal tracts with this infection (or colonization) being more common in developing countries. In recent decades, however, the prevalence of *H. pylori* colonization of the gastrointestinal tract has declined in many countries [5]. Up to 90% of people infected with *H. pylori* never experience symptoms or complications. However, individuals infected with *H. pylori* have a 10% to 20% lifetime risk of developing peptic ulcers [6]. Acute infection may appear as an acute gastritis with abdominal pain (stomach ache) or nausea. Where this develops into chronic gastritis, the symptoms, if present, are often those of non-ulcer dyspepsia: Stomach pains, nausea, bloating, belching, and sometimes vomiting. Pain typically occurs when the stomach is empty, between meals, and in the early morning hours, but it can also occur at other times. Less common ulcer symptoms include nausea, vomiting, and loss of appetite [7]. Bleeding in the stomach can also occur as evidenced by the passage of black stools; prolonged bleeding may cause anemia leading to weakness and fatigue. If bleeding is heavy, hematemesis, hematochezia, or melena may occur. Inflammation of the pyloric antrum, which connects the stomach to the duodenum, is more likely to lead to duodenal ulcers, while inflammation of the corpus (i.e. body of the stomach) is more likely to lead to gastric ulcers. [8]. Individuals with chronic *H. pylori* infection have an increased risk of acquiring a cancer that is directly related to this infection such as stomach cancer which is not common. [9].

Studies have revealed that the most common causes of ulcer disease are the bacteria *H. pylori* and Non-steroidal Anti-inflammatory Drugs (NSAIDs), [10]. The infections caused by this bacterium mostly progress from childhood and remain chronically (lifelong) without any

symptoms. Acute gastric infections, however, may be developed in some patients. [11]. *H. pylori* is a fastidious microorganism and requires complex growth media. Often these media are supplemented with blood or serum mixed with anti-microbial agents. [12].

The mode of transmission of *H. pylori* is not known exactly, but the fecal–oral or oral–oral routes via water or food consumption are thought to be a very common cause. [13]. As an example, mother-to-child transmission occurs if the mother’s saliva is contaminated or due to poor hand hygiene. The pathogen is transmitted by direct means, e.g., kissing or sharing utensils [14], or by indirect means, such as drinking water, air, animals, flies, and food [15]. While other microbes have been reported as causative agents of gastritis, there is need to ascertain the actual cause of these infections and risk factors associated with gastroenteritis related to *H. pylori* infections which include, living in crowded conditions, fecal contamination of food, water and utensils, lack of clean water and poor sanitary conditions etc. However, this research was intended to evaluate the prevalence of *Helicobacter pylori* infections among patients attending a Government Hospital in Port-Harcourt Rivers State Nigeria.

Comment [SA3]: Add a paragraph for diagnosis

2. Materials and Methods

2.1. Study design

A cross-sectional study was carried out using random sampling technique to group the subjects from August 2023 to February 2024

Comment [SA4]: Type of randomization?

2.2. Study Area

This study was conducted in a Government Hospital in Port-Harcourt, Rivers State Nigeria with GPS coordinates of 4°49'27"N 7°21"E.

2.3. Sample Collection

In this study, clinical data and information of patients were recorded using a well-structured questionnaire. A total of one hundred and five (105) stool samples were collected from patients (48 males and 57 females) aged 10 - ≥31 in a sterile screw-cap bottle (universal bottle) labeled with the specimens I.D number. The sample size was calculated using the formula: $n = Z^2 P (1 - P) / d^2$ [16] and a confidence level of 95%.

2.4. *H. pylori* Screening

2.4.1. *H. pylori* Antigenic Screening

H. pylori antibody test is a qualitative membrane-based immunoassay for the identification of *H. pylori* antibodies in blood, serum or plasma [17]. Stool samples were collected and tested using the *H. pylori* test strip kit (OnSite *H. pylori* Ag Rapid Test (cassette) CTK Biotech USA). Approx. 10g of stool samples was collected in a stool collection device containing 1ml sample extraction buffer and shaken firmly to ensure a homogenous liquid suspension. Few drops of the solution were dispensed into the sample well of the cassette and timed for 10 minutes, if only the control line (C line) develops, the test indicates that no detectable *H. pylori* antigen is present in the specimen. The result is negative or non-reactive. If both C and Test line (T line) develops, the test indicates the presence of detectable *H. pylori* antigen in the specimen. The result is positive or reactive. If no C line develops, the test is invalid regardless of any color development in the T line as described by the manufacturer.

2.4.2. Culture-based Technique

Primary isolation was carried out on Columbia agar with Dent selective supplement containing amphotericin B (25µl), vancomycin (50µl), trimethoprim (156.25µl) and ceftazidime (25µl) replaces cefsulodine [18], plus 10% horse blood. Using a sterile inoculating loop, inoculum of stool sample was aseptically streaked on the surface of the agar plates. Inverted, the plates were incubated in an anaerobic jar undisturbed with a micro-aerophilic kit GasPak (CO₂) AnaeroGen™, Oxoid, (Basingstoke, United Kingdom) for 3 days at 37°C in an anaerobic atmosphere (80% - 90% N₂, 5%-10% CO₂ and 5%-10% O₂). After 3 days, the plates were removed and visually inspected. When the colonies appeared too small, a new GasPak (CO₂) AnaeroGen™, Oxoid, kit was placed in the anaerobic jar and the plates re-incubated for a further 2 days. Pure cultures were harvested using a sterile inoculating loop to transfer discrete colonies of *H. pylori* into cryotubes containing 5ml brain heart infusion (BHI) broth enriched with 20% glycerol and stored at -80°C for further analysis. [19].

Comment [SA5]: Culture of this bacteria from stool is too difficult how could you obtained your results?

2.5. Morphological Characterization

Discrete colonies were picked from each culture plates and classified as *H. pylori* on the basis of typical colonial morphology (small and translucent colonies), the presence of curved gram-negative cells on Gram stain, urease, catalase, oxidase production, growth at 35 and 40°C, growth at (1.00 and 1.25% NaCl, growth at 0.5 and 0.75% NaCl) glucose fermentation, Hydrogen Sulfide (H₂S), motility test, selenite reduction and growth on MacConkey agar [20].

2.6. Statistical Analysis

Data analysis was performed using IBM (SPSS) version 22.0. The Chi-Square test was utilized to summarize all data obtained to determine the frequency and percentage of occurrence. *P*-value < 0.05 was determined as statistically significant.

3. Results and Discussion

3.1 Antigenic Screening/Culture-Based Detection Technique

Results of *H. pylori* gender prevalence for both antigenic screening and culture are presented in Fig 1. A total of 105 stool specimens were analyzed for this study, (45.7%) males and (54.3%) females. (21.9%) male and (31.4%) female turned out positive for antigenic screening making *H. pylori* infection in females relatively high with no gender associated significance (*P*>0.05) between the male and female participants.

However, for culture, the total positive male was (2.9%) and (4.7%) for females. With no significant difference (*P*>0.05), the prevalence of *H. pylori* infections was relatively low according to gender in male compared to that recovered from the female according to this study.

3.2 Age Group Prevalence using Antigenic Screening/Culture-Based Detection Technique

The ratio of prevalence among the different age groups for both antigenic and culture ranged between 10 - ≥31 years. *H. pylori* infection increased generally with age between (4.8%) to (20.0%) for antigenic screening.

Culture reported low frequency of (3.8%) between age group 26 - ≥31 respectively, while the least recovery was observed within age group 21-25 years and below, lowest than other age groups as provided in Fig.2. There was no significant difference (*P*>0.05) between age group of participants using antigenic screening and culture-based technique.

3.3 Overall Prevalence According to Antigenic Screening/Culture-based Technique

Overall prevalence of *H. pylori* in Port-Harcourt varied from (53.3%) to (7.6%) according to antigenic screening and culture as shown in Fig 3 for all specimens evaluated in this study with significant difference ($P < 0.05$), while (46.7%) tested negative for antigenic screening and (0.0%) were classified as negative by culture. *H. pylori* infections were observed to be relatively high for antigenic screening than that obtained by culture.




Fig1: Prevalence of *H. pylori* using antigenic screening and culture-based technique among the population gender in the study.




Fig 2: Prevalence of *H. pylori* among the different age group (years) in the study using antigenic screening and culture-based technique.




Fig 3. Overall prevalence of *H. pylori* among the population using antigenic screening and culture-based technique.

4. Discussion

The detection of *H. pylori* from stool using antigenic screening and culture-based technique in a government hospital in Port-Harcourt, Rivers State Nigeria revealed that antigenic screening was highly sensitive in the detection of *H. pylori* with culture recording the least recovery.

The current study identified variations in the detection of *H. pylori* using antigenic and culture-based technique. The percentage of total positive cases identified using antigenic screening revealed high percentage of prevalence than that recovered by culture respectively. [21] reported that detection rate by antigenic screening were higher than that obtained by culture. This report is in agreement with the present study where a greater percentage of prevalence was observed using antigenic screening than that obtained by culture. This could possibly be due to lack of viable cells or the difficulty of adapting appropriate isolation techniques

Population prevalence varied relatively in both genders and age groups (years). Although it is unclear if gender and age group are risk factors in the heightened prevalence observed among the females than in the males for both antigenic screening and culture. These observations is in dispute with the current worldwide *H. pylori* prevalence study which revealed no differences in *H. pylori* infection among male and female genders. [22].

Age group prevalence generally increased with age ranging from 10- \geq 31 years for antigenic screening. However, culture for age group between 10-25 age group recorded the least recovery while 26- \geq 31 age group revealed low results respectively. These observations were in contrast with [23] who reported a higher prevalence of adult participants aged 16 and \geq 30 years. There was no significant difference in the gender and age group prevalence of *H. pylori* among the studied population. This could be probably due to living in crowded conditions, fecal contamination of food, water and utensils, lack of clean water and poor sanitary conditions etc. [24;25]. Females should often be educated on the importance of personal hygiene practices as they are majorly involved in taking care of the family as this could play an important role in the transmission of infection.

However, these diagnostic techniques have their advantages and limitations but none of them can be considered gold standard as a single test for the diagnosis of *H. pylori* infection according to reports[26].

5. Conclusion

The diagnosis of *H. pylori* infection by antigenic screening has proven to be highly sensitive in the detection of *H. pylori* infection than culture in this study.

Findings of this study revealed a high percentage of *H. pylori* infection among the female than the male gender, also age-group prevalence was found to be high among age-groups 26-30 and ≥ 31 age-groups compared to other age group of 25 years and below for both antigenic screening and culture-based technique in this study.

References

1. Alfarouk, K. O., Bashir, A. H., Aljarbou, A. N., Ramadan, A. M., Muddathir, A. K., and AlHoufie, S.T. (2019). "*Helicobacter pylori* in Gastric Cancer and Its Management". *Frontiers in Oncology*. 9: 75.
2. Rust, M., Schweinitzer, T., and Josenhans C (2008). Helicobacter Flagella, Motility and Chemotaxis». In Yamaoka, Y. (ed.). *Helicobacter pylori: Molecular Genetics and Cellular Biology*. Caister Academic Press. ISBN 978-1-904455-31-8. Archived from the original on 18 August 2016. Retrieved 1 April 2008.
3. Salama, N. R. (2020). "Cell morphology as a virulence determinant: lessons from *Helicobacter pylori*". *Curr Opin Microbiol*. 54: 11–17.
4. Blaser, M. J. (2006). "Who are we? Indigenous microbes and the ecology of human diseases". *EMBO Reports*. 7 (10): 956–60
5. Minalyan, A, Gabrielyan, L, Scott, D., Jacobs, J., and Pisegna, J. R. (2017). "The Gastric and Intestinal Microbiome: Role of Proton Pump Inhibitors". *Current Gastroenterology Reports*. 19 (8): 42.
6. Bytzer, P., Dahlerup, J. F., Eriksen, J. R., Jarbøl, D. E., Rosenstock, S., and Wildt, S. (2011). "Diagnosis and treatment of *Helicobacter pylori* infection". *Danish Medical Bulletin*. 58(4): C4271.
7. Ryan, K. (2010). *Sherris Medical Microbiology*. McGraw-Hill. pp. 573, 576.
8. Wagner, A. D., Syn N. L, Moehler, M., Grothe W., Yong W. P., and Tai, B. C. (2017). "Chemotherapy for advanced gastric cancer". *The Cochrane Database of Systematic Reviews*. 8: CD004064.
9. Chang, A. H., and Parsonnet, J. (2010). "Role of bacteria in oncogenesis". *Clinical Microbiology Reviews*. 23(4): 837–857.

10. Najm, W. I. (2011). "Peptic ulcer disease". *Primary Care*. 38 (3): 383–94.
11. Blanchard, T. G., and Czinn S. J., (2017). Identification of *Helicobacter pylori* and the evolution of an efficacious childhood vaccine to protect against gastritis and peptic ulcer disease. *Pediatr Res*. 81:170–176.
12. Taneera, J., Moran, A. P., Hynes, S.O., Nilsson, H. O., Al-Soud, W., and Wadstrom, T. (2002). Influence of activated charcoal, porcine gastric mucin and beta-cyclodextrin on the morphology and growth of intestinal and gastric *Helicobacter spp.* *Microbiology*. 148: 677-684.
13. Brown, L. M. (2000). "*Helicobacter pylori*: epidemiology and routes of transmission". *Epidemiol. Rev.* 22: 283–297.
14. Brenner, H., Rothenbacher D., Bode G., Dieudonne P., Adler G. (1999) Active infection with *Helicobacter pylori* in healthy couples. *Epidemiology and infection*, 122:91-95.
15. Allaker, R. P., K. A. Young., J. M. Hardie., P. Domizio, and N. J. Meadows (2002) "Prevalence of *Helicobacter pylori* at oral and gastrointestinal sites in children: evidence for possible oral-to-oral transmission". *Journal of Medical Microbiology*, vol. 15, 4:312-317
16. Naing, L., Winn, T., and Rusli, B. N. (2006). Practical Issues in Calculating the Sample size for Prevalence Studies. *Archives of Orofacial Science*, 1: 9-14.
17. Ultimate Medical Products (2022). IVD manufacturer and drug screening experts. <https://www.ultimed.org/produkte/h-pylori-antibody-test/.012L400>
18. Dent, J. C., and C. A. McNulty. (1988). Evaluation of a new selective medium for *Campylobacter pylori*. *Eur. J. Clin. Microbiol. Infect. Dis.*7:555-558.
19. Kimang'a, A. N., Gunturu R., Samuel k., Shahin S., and Smita D. (2010). *Helicobacter Pylori*: Prevalence and antibiotic susceptibility among Kenyans. *S. Afr. Med. J.* 100 (1):53-57.
20. Sreenivasan, S., and Abdul, M. U. (2009). Development and evaluation of a new growth medium for *Helicobacter pylori* *FEMS Immunology & Medical Microbiology*. Vol. 56 (1) Pp 94–97.
21. Jhoan, F. G., Isidro, F. B., Veronica, A., Angelica, T., Araceli, L., Sonia, S., Juan, G., and Rivelino, R. C. (2018). Detection of *Helicobacter pylori* from Human Biological Samples (Feces) by Antigenic Screening and Culture. *Jundishapur J Microbiol.* 11 (7).
22. Zamani, M., Ebrahimitabar, F., Zamani, V., Miller, W. H., Alizadeh-Navaei, R., Shokri-Shirvani J., and Derakhshan M. H. (2018). Systematic review with meta-analysis: the worldwide prevalence of *Helicobacter pylori* infection. *Aliment. Pharmacol. Ther.* 47:868–876.

23. Ghalia, K., Jibrán, S. M., Ibrahim, M., Sameh, S.M.S., and Christophe, B. (2019). Prevalence of *Helicobacter pylori* and Its Associated Factors among Healthy Asymptomatic Residents in the United Arab Emirates. *Pathogens*. 1;8 (2):44.
24. Kouitcheu, Mabeku, L. B., NoundjeuNgamga M. L. and Leundji, H. (2018). Potential risk factors and prevalence of *Helicobacter pylori* infection among adult patients with dyspepsia symptoms in Cameroon. *BMC Infectious Diseases*.18 (1):278.
25. Krueger, W., Hilborn E., and Converse R, *et al.* (2015). Environmental risk factors associated with *Helicobacter pylori* seroprevalence in the United States: A cross-sectional analysis of NHANES data. *Epidemiology and Infection*. Cambridge University Press, New York, NY, 143(12):2520-31.
26. Miftahussurur, M., and Yamaoka, Y. (2016) Diagnostic Methods of *Helicobacter pylori* Infection for Epidemiological Studies: Critical Importance of Indirect Test Validation. *Biomed Res Int*. 2016:4819423.